Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies

Circulation Research

Volumn 117, Issue 5, 2015, Pages 470-482

  Loupy, Alexandre ^a,b   Vernerey, Dewi ^d   Viglietti, Denis ^a,c   Aubert, Olivier ^a   Duong Van Huyen, Jean Paul ^a,b,e   Empana, Jean Philippe ^a   Bruneval, Patrick ^a,f   Glotz, Denis ^a,c   Legendre, Christophe ^a,b   Jouven, Xavier ^a,g   Lefaucheur, Carmen ^a,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f Georges Pompidou European Hospital ^*  (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

antibodies; arteriosclerosis; cardiovascular diseases; transplantation

Indexed keywords

ANTIBODY; CIRCULATING ANTIBODY; HLA ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; HLA ANTIGEN;

ACUTE CORONARY SYNDROME; ADULT; ANTIHYPERTENSIVE THERAPY; ARTERIOSCLEROSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COLD ISCHEMIA; COMPLEMENT DEPOSITION; COMPLEMENT FIXATION; DIABETES MELLITUS; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HLA SYSTEM; HLA TYPING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; AGED; ALLOTRANSPLANTATION; BLOOD; FOLLOW UP; GRAFT REJECTION; KIDNEY TRANSPLANTATION; PHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME; TRENDS;

ADULT; AGED; ARTERIOSCLEROSIS; AUTOANTIBODIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84939505153     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.306340     Document Type: Article

References (53)

1. Libby P, Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 2003 91 3A 6A
2. Libby P, Zhao DX, Allograft arteriosclerosis and immune-driven angiogenesis. Circulation 2003 107 1237 1239
3. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM, Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000 20 1262 1275
4. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM, Board of the EURECA-m Working Group of ERA-EDTA Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014 383 1831 1843. doi: 10.1016/S0140-6736(14)60384-6.
5. Hill GS, Nochy D, Bruneval P, Duong van Huyen JP, Glotz D, Suberbielle C, Zuber J, Anglicheau D, Empana JP, Legendre C, Loupy A, Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011 22 975 983. doi: 10.1681/ASN.2010070777.
6. Hill GS, Nochy D, Loupy A, Accelerated arteriosclerosis: a form of transplant arteriopathy. Curr Opin Organ Transplant 2010 15 11 15. doi: 10.1097/MOT.0b013e3283342684.
7. Loupy A, Cazes A, Guillemain R, Amrein C, Hedjoudje A, Tible M, Pezzella V, Fabiani JN, Suberbielle C, Nochy D, Hill GS, Empana JP, Jouven X, Bruneval P, Duong Van Huyen JP, Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant 2011 11 1478 1487. doi: 10.1111/j.1600-6143.2011.03563.x.
8. Go AS, Mozaffarian D, Roger VL, American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014 129 e28 e292. doi: 10.1161/01.cir.0000441139.02102.80.
9. Lorenz MW, Polak JF, Kavousi M, PROG-IMT Study Group Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012 379 2053 2062. doi: 10.1016/S0140-6736(12)60441-3.
10. Polak JF, Pencina MJ, O'Leary DH, D'Agostino RB, Common carotid artery intima-media thickness progression as a predictor of stroke in multi-ethnic study of atherosclerosis. Stroke 2011 42 3017 3021. doi: 10.1161/STROKEAHA.111.625186.
11. Hansson GK, Hermansson A, The immune system in atherosclerosis. Nat Immunol 2011 12 204 212. doi: 10.1038/ni.2001.
12. Hansson GK, Robertson AK, Söderberg-Nauclér C, Inflammation and atherosclerosis. Annu Rev Pathol 2006 1 297 329. doi: 10.1146/annurev.pathol.1.110304.100100.
13. Packard RR, Lichtman AH, Libby P, Innate and adaptive immunity in atherosclerosis. Semin Immunopathol 2009 31 5 22. doi: 10.1007/s00281-009-0153-8.
14. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE, Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003 349 2399 2406. doi: 10.1056/NEJMoa035471.
15. Descombes E, Droz D, Drouet L, Grünfeld JP, Lesavre P, Renal vascular lesions in lupus nephritis. Medicine (Baltimore) 1997 76 355 368
16. Nochy D, Daugas E, Droz D, Beaufils H, Grünfeld JP, Piette JC, Bariety J, Hill G, The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999 10 507 518
17. Ludewig B, Freigang S, Jäggi M, Kurrer MO, Pei YC, Vlk L, Odermatt B, Zinkernagel RM, Hengartner H, Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci USA 2000 97 12752 12757. doi: 10.1073/pnas.220427097.
18. Getz GS, Reardon CA, Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol 2012 32 1104 1115. doi: 10.1161/ATVBAHA.111.237693.
19. Bentzon JF, Falk E, Atherosclerotic lesions in mouse and man: is it the same disease? Curr Opin Lipidol 2010 21 434 440. doi: 10.1097/MOL.0b013e32833ded6a.
20. Avery RK, Cardiac-allograft vasculopathy. N Engl J Med 2003 349 829 830. doi: 10.1056/NEJMp038124.
21. Wehner J, Morrell CN, Reynolds T, Rodriguez ER, Baldwin WM 3rd, Antibody and complement in transplant vasculopathy. Circ Res 2007 100 191 203. doi: 10.1161/01.RES.0000255032.33661.88.
22. Schmauss D, Weis M, Cardiac allograft vasculopathy: recent developments. Circulation 2008 117 2131 2141. doi: 10.1161/CIRCULATIONAHA.107.711911.
23. Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, Madsen J, Parameshwar J, Starling RC, Uber PA, International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010 29 717 727. doi: 10.1016/j.healun.2010.05.017.
24. Nankivell BJ, Alexander SI, Rejection of the kidney allograft. N Engl J Med 2010 363 1451 1462. doi: 10.1056/NEJMra0902927.
25. Colvin RB, Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007 18 1046 1056. doi: 10.1681/ASN.2007010073.
26. Lefaucheur C, Loupy A, Vernerey D, Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013 381 313 319. doi: 10.1016/S0140-6736(12)61265-3.
27. Données Informatiques VAlidées en Transplantation: http://divat.idbc.fr/
28. Solez K, Colvin RB, Racusen LC, Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008 8 753 760. doi: 10.1111/j.1600-6143.2008.02159.x.
29. Sis B, Mengel M, Haas M, Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010 10 464 471. doi: 10.1111/j.1600-6143.2009.02987.x.
30. Racusen LC, Solez K, Colvin RB, The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 713 723. doi: 10.1046/j.1523-1755.1999.00299.x.
31. Haas M, Sis B, Racusen LC, Banff meeting report writing committee Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014 14 272 283. doi: 10.1111/ajt.12590.
32. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C, Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010 21 1398 1406. doi: 10.1681/ASN.2009101065.
33. Loupy A, Lefaucheur C, Vernerey D, Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013 369 1215 1226. doi: 10.1056/NEJMoa1302506.
34. CRISTAL, Agence Biomédecine: https://http://www.sipg.sante.fr/portail/
35. Loupy A, Hill GS, Jordan SC, The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012 8 348 357. doi: 10.1038/nrneph.2012.81.
36. Young JB, Neumayer HH, Gordon RD, Pretransplant cardiovascular evaluation and posttransplant cardiovascular risk. Kidney Int Suppl 2010 S1 S7
37. Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, Carithers RL, Ragosta M, Bolton K, Auerbach AD, Eagle KA, American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Peripheral Vascular Disease; American Heart Association; American College of Cardiology Foundation Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. Circulation 2012 126 617 663. doi: 10.1161/CIR.0b013e31823eb07a.
38. Gigante B, Leander K, Vikström M, IMPROVE Study Group Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men. Atherosclerosis 2014 236 394 399. doi: 10.1016/j.atherosclerosis.2014.07.030.
39. Gómez M, Vila J, Elosua R, Molina L, Bruguera J, Sala J, Masià R, Covas MI, Marrugat J, Fitó M, Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population. Atherosclerosis 2014 232 134 140. doi: 10.1016/j.atherosclerosis.2013.10.026.
40. Arvanitakis Z, Brey RL, Rand JH, Schneider JA, Capuano AW, Yu L, Leurgans SE, Bennett DA, Levine SR, Relation of antiphospholipid antibodies to postmortem brain infarcts in older people. Circulation 2015 131 182 189. doi: 10.1161/CIRCULATIONAHA.114.012479.
41. Cai J, Terasaki PI, Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 2005 66 334 342. doi: 10.1016/j.humimm.2005.01.021.
42. Bian H, Reed EF, Anti-HLA class I antibodies transduce signals in endothelial cells resulting in FGF receptor translocation, down-regulation of ICAM-1 and cell proliferation. Transplant Proc 2001 33 311
43. Bieri M, Oroszlan M, Farkas A, Ligeti N, Bieri J, Mohacsi P, Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability. Int J Biochem Cell Biol 2009 41 2422 2430. doi: 10.1016/j.biocel.2009.06.009.
44. Frank R, Molina MR, Wald JW, Goldberg LR, Kamoun M, Lal P, Correlation of circulating donor-specific anti-HLA antibodies and presence of C4d in endomyocardial biopsy with heart allograft outcomes: a single-center, retrospective study. J Heart Lung Transplant 2013 32 410 417. doi: 10.1016/j.healun.2012.12.005.
45. Uehara S, Chase CM, Cornell LD, Madsen JC, Russell PS, Colvin RB, Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transplant 2007 7 57 65. doi: 10.1111/j.1600-6143.2006.01599.x.
46. Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P, Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998 394 200 203. doi: 10.1038/28204.
47. Lundberg AM, Hansson GK, Innate immune signals in atherosclerosis. Clin Immunol 2010 134 5 24. doi: 10.1016/j.clim.2009.07.016.
48. Hansson GK, Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 1685 1695. doi: 10.1056/NEJMra043430.
49. Hermansson A, Ketelhuth DF, Strodthoff D, Wurm M, Hansson EM, Nicoletti A, Paulsson-Berne G, Hansson GK, Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 2010 207 1081 1093. doi: 10.1084/jem.20092243.
50. Blake GJ, Ostfeld RJ, Yucel EK, Varo N, Schönbeck U, Blake MA, Gerhard M, Ridker PM, Libby P, Lee RT, Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol 2003 23 e11 e14
51. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, Ren B, Fu XD, Topol EJ, Rosenfeld MG, Frazer KA, 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature 2011 470 264 268. doi: 10.1038/nature09753.
52. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA, Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002 100 3853 3860. doi: 10.1182/blood.V100.12.3853.
53. Duewell P, Kono H, Rayner KJ, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010 464 1357 1361. doi: 10.1038/nature08938.